|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Shen L, Shan YS, Hu HM, Price TJ, Sirohi
B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al: Management of
gastric cancer in Asia: Resource-stratified guidelines. Lancet
Oncol. 14:e535–e547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pasini F, Fraccon AP and DE Manzoni G: The
role of chemotherapy in metastatic gastric cancer. Anticancer Res.
31:3543–3554. 2011.PubMed/NCBI
|
|
4
|
Matt P, van Zwieten-Boot B, Calvo Rojas G,
Ter Hofstede H, Garcia-Carbonero R, Camarero J, Abadie E and
Pignatti F: The European medicines agency review of
Tegafur/Gimeracil/Oteracil (TeysunoT™) for the treatment of
advanced gastric cancer when given in combination with cisplatin:
Summary of the scientific assessment of the committee for medicinal
products for human use (CHMP). Oncologist. 16:1451–1457. 2011.
View Article : Google Scholar
|
|
5
|
Okuno T, Shirotsuki J, Murahashi K and
Sawada T: Advanced gastric cancer (stage IV) leading to perforation
during chemotherapy with S-1 plus cisplatin. Gan To Kagaku Ryoho.
41:1313–1315. 2014.In Japanese. PubMed/NCBI
|
|
6
|
Sasaki T and Kuniyasu H: Significance of
AKT in gastric cancer (Review). Int J Oncol. 45:2187–2192.
2014.PubMed/NCBI
|
|
7
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar
|
|
8
|
Radisavljevic Z: AKT as locus of cancer
multidrug resistance and fragility. J Cell Physiol. 228:671–674.
2013. View Article : Google Scholar
|
|
9
|
Nam SY, Lee HS, Jung GA, Choi J, Cho SJ,
Kim MK, Kim WH and Lee BL: Akt/PKB activation in gastric carcinomas
correlates with clinicopathologic variables and prognosis. APMIS.
111:1105–1113. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang LL, Zhang J, Shen L, Xu XM and Yu
HG: Overexpression of AKT decreases the chemosensitivity of gastric
cancer cells to cisplatin in vitro and in vivo. Mol Med Rep.
7:1387–1390. 2013.PubMed/NCBI
|
|
11
|
Zhang J, Zhang LL, Shen L, Xu XM and Yu
HG: Regulation of AKT gene expression by cisplatin. Oncol Lett.
5:756–760. 2013.PubMed/NCBI
|
|
12
|
Park J, Ko YS, Yoon J, Kim MA, Park JW,
Kim WH, Choi Y, Kim JH, Cheon Y and Lee BL: The forkhead
transcription factor FOXO1 mediates cisplatin resistance in gastric
cancer cells by activating phosphoinositide 3-kinase/Akt pathway.
Gastric Cancer. 17:423–430. 2014. View Article : Google Scholar
|
|
13
|
Sun XP, Dong X, Lin L, Jiang X, Wei Z,
Zhai B, Sun B, Zhang Q, Wang X, Jiang H, et al: Up-regulation of
survivin by AKT and hypoxia-inducible factor 1α contributes to
cisplatin resistance in gastric cancer. FEBS J. 281:115–128. 2014.
View Article : Google Scholar
|
|
14
|
Rohwer N, Dame C, Haugstetter A,
Wiedenmann B, Detjen K, Schmitt CA and Cramer T: Hypoxia-inducible
factor 1alpha determines gastric cancer chemosensitivity via
modulation of p53 and NF-kappaB. PLoS One. 5:e120382010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Adamski J, Price A, Dive C and Makin G:
Hypoxia-induced cytotoxic drug resistance in osteosarcoma is
independent of HIF-1alpha. PLoS One. 8:e653042013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rankin EB and Giaccia AJ: The role of
hypoxia-inducible factors in tumorigenesis. Cell Death Differ.
15:678–685. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee SH, Jee JG, Bae JS, Liu KH and Lee YM:
A group of novel hif-1alpha inhibitors, glyceollins, blocks
HIF-1alpha synthesis and decreases its stability via inhibition of
the PI3K/AKT/mTOR pathway and Hsp90 binding. J Cell Physiol.
230:853–862. 2014. View Article : Google Scholar
|
|
19
|
Kim BR, Yoon K, Byun HJ, Seo SH, Lee SH
and Rho SB: The anti-tumor activator sMEK1 and paclitaxel
additively decrease expression of HIF-1α and VEGF via
mTORC1-S6K/4E-BP-dependent signaling pathways. Oncotarget.
5:6540–6551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Z, Luo H, Wang H and Hou H:
Preparative isolation of bufalin and cinobufagin from Chinese
traditional medicine Chansu. J Chromatogr Sci. 46:81–85. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu F, Han J, Zhai B, Ming X, Zhuang L, Liu
Y, Pan S and Liu T: Blocking autophagy enhances the apoptosis
effect of bufalin on human hepatocellular carcinoma cells through
endoplasmic reticulum stress and JNK activation. Apoptosis.
19:210–223. 2014. View Article : Google Scholar
|
|
22
|
Zhang ZJ, Yang YK and Wu WZ: Bufalin
attenuates the stage and metastatic potential of hepatocellular
carcinoma in nude mice. J Transl Med. 12:572014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu Z, Sun H, Ma G, Wang Z, Li E and Liu Y
and Liu Y: Bufalin induces lung cancer cell apoptosis via the
inhibition of PI3K/Akt pathway. Int J Mol Sci. 13:2025–2035. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li M, Yu X, Guo H, Sun L, Wang A, Liu Q,
Wang X and Li J: Bufalin exerts antitumor effects by inducing cell
cycle arrest and triggering apoptosis in pancreatic cancer cells.
Tumour Biol. 35:2461–2471. 2014. View Article : Google Scholar
|
|
25
|
Tsai SC, Lu CC, Lee CY, Lin YC, Chung JG,
Kuo SC, Amagaya S, Chen FN, Chen MY and Chan SF: AKT
serine/threonine protein kinase modulates bufalin-triggered
intrinsic pathway of apoptosis in CAL 27 human oral cancer cells.
Int J Oncol. 41:1683–1692. 2012.PubMed/NCBI
|
|
26
|
Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu
B, Pan S, Dong X, Tan G, Wei Z, et al: Inhibition of Akt reverses
the acquired resistance to sorafenib by switching protective
autophagy to autophagic cell death in hepatocellular carcinoma. Mol
Cancer Ther. 13:1589–1598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao D, Zhai B, He C, Tan G, Jiang X, Pan
S, Dong X, Wei Z, Ma L, Qiao H, et al: Upregulation of HIF-2α
induced by sorafenib contributes to the resistance by activating
the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Cell
Signal. 26:1030–1039. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge
Y, Newman RA, Cohen L, Liu L, Thornton B, et al: Pilot study of
huachansu in patients with hepatocellular carcinoma, nonsmall-cell
lung cancer, or pancreatic cancer. Cancer. 115:5309–5318. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dillon RL and Muller WJ: Distinct
biological roles for the akt family in mammary tumor progression.
Cancer Res. 70:4260–4264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Molife LR, Yan L, Vitfell-Rasmussen J,
Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E,
Siu LL, et al: Phase 1 trial of the oral AKT inhibitor MK-2206 plus
carboplatin/paclitaxel, docetaxel, or erlotinib in patients with
advanced solid tumors. J Hematol Oncol. 7:12014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Davies BR, Greenwood H, Dudley P, Crafter
C, Yu DH, Zhang J, Li J, Gao B, Ji Q, Maynard J, et al: Preclinical
pharmacology of AZD5363, an inhibitor of AKT: Pharmacodynamics,
antitumor activity and correlation of monotherapy activity with
genetic background. Mol Cancer Ther. 11:873–887. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stronach EA, Chen M, Maginn EN, Agarwal R,
Mills GB, Wasan H and Gabra H: DNA-PK mediates AKT activation and
apoptosis inhibition in clinically acquired platinum resistance.
Neoplasia. 13:1069–1080. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li M, Balch C, Montgomery JS, Jeong M,
Chung JH, Yan P, Huang TH, Kim S and Nephew KP: Nephew, Integrated
analysis of DNA methylation and gene expression reveals specific
signaling pathways associated with platinum resistance in ovarian
cancer. BMC Med Genomics. 2:342009. View Article : Google Scholar
|
|
36
|
Stegeman H, Kaanders JH, Wheeler DL, van
der Kogel AJ, Verheijen MM, Waaijer SJ, Iida M, Grénman R, Span PN
and Bussink J: Activation of AKT by hypoxia: A potential target for
hypoxic tumors of the head and neck. BMC Cancer. 12:4632012.
View Article : Google Scholar : PubMed/NCBI
|
